Neal D. Shore, MD, on the Importance of Multidisciplinary Care in Advanced Prostate Cancer

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Neal D. Shore, MD, FACS, regarding the importance of multidisciplinary care for patients with advanced prostate cancer.

Incorporating a multidisciplinary approach for patients with advanced prostate cancer is essential in order to provide patients with further therapeutic benefit and improve quality of life.

Transcript:

When we are taking care of our patients with advanced cancers, and advanced prostate cancer is no exception, fatigue and the spectrum of neurocognitive maladies, as well as cardio-oncologic maladies become that much more important. All across the field of cancer in its totality, [we] are recognizing this. [By] incorporating a multidisciplinary approach, either as the [urologic] oncologist, the medical oncologist, the radiation oncologist, the nuclear medicine radiologist, or the pathologist—whoever is really involved in the care of the patient—appreciating that the spectrum of cardio-oncologic and neuro-oncologic differences in drugs of the same therapeutic class need to be studied [is important]. It may not affect all patients, it may not affect most patients, but there [are] clearly going to be certain patients or a significant population of patients [for whom] the right drug selection and comparable therapeutic mechanism of action classes could really benefit a patient and help their quality of life.